ClinicalTrials.gov
public full text
Public Domain
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME#839267
- A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors#981443
- A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)#866107
- A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD#882628
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors#899717
Record · ID 849338
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive